2026 Q2 - tulosraportti
58 päivää sitten
‧40 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 500 | - | - | ||
| 48 | - | - | ||
| 5 000 | - | - | ||
| 188 | - | - | ||
| 1 822 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 5.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 6.8. | ||
2026 Q1 - tulosraportti 7.5. | ||
2025 Q4 - tulosraportti 24.2. | ||
2025 Q3 - tulosraportti 26.11.2025 | ||
2025 Q2 - tulosraportti 28.8.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
12 t sittenI don't have any exposure, have no short positions or anything else that will benefit me if this stock fall now. I only hope my action now will finally lead to close this company down. I think I have deep knowledge of the company, the market they are trying to enter, their competitors and the US approval system. What is key, is the way passing through FDA and getting in to the Medicare system. Immunovia is not close even to get a preliminary opinion from FDA. If anyone in this forum like to contact me you can do it on this forum. Everything from the Immunovia product reletive to competitors, blood tests for cancer detection, cost/benefit analyses. The way through FDA to Medicare approval. I am totally independent, my only benefit will be when I see this scam stopped
What FDA? They haven't even tried to get any approval from the FDA since their lab is CLIA-certified and doesn't need it.- ·18 t sittenCome on now all sellers. 10-15% down to that and rights issue will be impossible. Immunovia go bankrupt. And no fat fees to Carlssquare
They have to issue billions of new shares to finance the rights issue. Everyone who wants to join will become billionaires in shares. Personally, I am glad I got out in time, now I can finally sleep at night. - ·1 päivä sittenCarlsquare is involved again in this issue (fraud). Boycott all contacts with them
- ·1 päivä sittenGrail, the only company close to getting an FDA approval for their Galleri blood test . Opens up Medicare in the US for them. Only competitor mentioned is Abbot Labs in Chicago. Immo is not even mentioned as a competitor. NO MORE MONEY TO THIS COMPANY,I have carried this anger for 5 years after taking a huge hit in this company in 2022. When the rights issue was announced this week, that was when everything snapped.
·1 päivä sitten · MuokattuObs. Have no personal gain or motive to buy back into Immunovia for a while. This is also no stock recommendation. I am only telling what I myself did today. Did not sell out completely, but significantly reduced IMMNOV at extortionate prices. But I myself see the necessity of trying to make money. With Japan on the starting line to build a new "fab" I think myself then, that Dutch ASML can go higher. They do have a monopoly after all on "EUV". That is on the lithography equipment itself. Should rather have had the money there. If Taiwan loses its territory, if, but something I do not think will happen so easily. Yes then Western countries will be in a hurry to roll out new "fabs" too. Such a just-in-case mindset I have. Maybe it then happens just because of the China threat, also without invasion? Possibility of precautionary actions in the West probably exists. But a bit far-fetched mindset. Anyway AI takes over, the biggest urge for chip production. The urge for chip lithography at least does not disappear anytime soon
Don't forget Applied Material (AMAT), they are behind all relevant manufacturing technology
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
58 päivää sitten
‧40 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- 12 t sittenI don't have any exposure, have no short positions or anything else that will benefit me if this stock fall now. I only hope my action now will finally lead to close this company down. I think I have deep knowledge of the company, the market they are trying to enter, their competitors and the US approval system. What is key, is the way passing through FDA and getting in to the Medicare system. Immunovia is not close even to get a preliminary opinion from FDA. If anyone in this forum like to contact me you can do it on this forum. Everything from the Immunovia product reletive to competitors, blood tests for cancer detection, cost/benefit analyses. The way through FDA to Medicare approval. I am totally independent, my only benefit will be when I see this scam stoppedWhat FDA? They haven't even tried to get any approval from the FDA since their lab is CLIA-certified and doesn't need it.
- ·18 t sittenCome on now all sellers. 10-15% down to that and rights issue will be impossible. Immunovia go bankrupt. And no fat fees to CarlssquareThey have to issue billions of new shares to finance the rights issue. Everyone who wants to join will become billionaires in shares. Personally, I am glad I got out in time, now I can finally sleep at night.
- ·1 päivä sittenCarlsquare is involved again in this issue (fraud). Boycott all contacts with them
- ·1 päivä sittenGrail, the only company close to getting an FDA approval for their Galleri blood test . Opens up Medicare in the US for them. Only competitor mentioned is Abbot Labs in Chicago. Immo is not even mentioned as a competitor. NO MORE MONEY TO THIS COMPANY,I have carried this anger for 5 years after taking a huge hit in this company in 2022. When the rights issue was announced this week, that was when everything snapped.
- ·1 päivä sitten · MuokattuObs. Have no personal gain or motive to buy back into Immunovia for a while. This is also no stock recommendation. I am only telling what I myself did today. Did not sell out completely, but significantly reduced IMMNOV at extortionate prices. But I myself see the necessity of trying to make money. With Japan on the starting line to build a new "fab" I think myself then, that Dutch ASML can go higher. They do have a monopoly after all on "EUV". That is on the lithography equipment itself. Should rather have had the money there. If Taiwan loses its territory, if, but something I do not think will happen so easily. Yes then Western countries will be in a hurry to roll out new "fabs" too. Such a just-in-case mindset I have. Maybe it then happens just because of the China threat, also without invasion? Possibility of precautionary actions in the West probably exists. But a bit far-fetched mindset. Anyway AI takes over, the biggest urge for chip production. The urge for chip lithography at least does not disappear anytime soonDon't forget Applied Material (AMAT), they are behind all relevant manufacturing technology
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 500 | - | - | ||
| 48 | - | - | ||
| 5 000 | - | - | ||
| 188 | - | - | ||
| 1 822 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 5.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 6.8. | ||
2026 Q1 - tulosraportti 7.5. | ||
2025 Q4 - tulosraportti 24.2. | ||
2025 Q3 - tulosraportti 26.11.2025 | ||
2025 Q2 - tulosraportti 28.8.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
58 päivää sitten
‧40 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 5.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 6.8. | ||
2026 Q1 - tulosraportti 7.5. | ||
2025 Q4 - tulosraportti 24.2. | ||
2025 Q3 - tulosraportti 26.11.2025 | ||
2025 Q2 - tulosraportti 28.8.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- 12 t sittenI don't have any exposure, have no short positions or anything else that will benefit me if this stock fall now. I only hope my action now will finally lead to close this company down. I think I have deep knowledge of the company, the market they are trying to enter, their competitors and the US approval system. What is key, is the way passing through FDA and getting in to the Medicare system. Immunovia is not close even to get a preliminary opinion from FDA. If anyone in this forum like to contact me you can do it on this forum. Everything from the Immunovia product reletive to competitors, blood tests for cancer detection, cost/benefit analyses. The way through FDA to Medicare approval. I am totally independent, my only benefit will be when I see this scam stoppedWhat FDA? They haven't even tried to get any approval from the FDA since their lab is CLIA-certified and doesn't need it.
- ·18 t sittenCome on now all sellers. 10-15% down to that and rights issue will be impossible. Immunovia go bankrupt. And no fat fees to CarlssquareThey have to issue billions of new shares to finance the rights issue. Everyone who wants to join will become billionaires in shares. Personally, I am glad I got out in time, now I can finally sleep at night.
- ·1 päivä sittenCarlsquare is involved again in this issue (fraud). Boycott all contacts with them
- ·1 päivä sittenGrail, the only company close to getting an FDA approval for their Galleri blood test . Opens up Medicare in the US for them. Only competitor mentioned is Abbot Labs in Chicago. Immo is not even mentioned as a competitor. NO MORE MONEY TO THIS COMPANY,I have carried this anger for 5 years after taking a huge hit in this company in 2022. When the rights issue was announced this week, that was when everything snapped.
- ·1 päivä sitten · MuokattuObs. Have no personal gain or motive to buy back into Immunovia for a while. This is also no stock recommendation. I am only telling what I myself did today. Did not sell out completely, but significantly reduced IMMNOV at extortionate prices. But I myself see the necessity of trying to make money. With Japan on the starting line to build a new "fab" I think myself then, that Dutch ASML can go higher. They do have a monopoly after all on "EUV". That is on the lithography equipment itself. Should rather have had the money there. If Taiwan loses its territory, if, but something I do not think will happen so easily. Yes then Western countries will be in a hurry to roll out new "fabs" too. Such a just-in-case mindset I have. Maybe it then happens just because of the China threat, also without invasion? Possibility of precautionary actions in the West probably exists. But a bit far-fetched mindset. Anyway AI takes over, the biggest urge for chip production. The urge for chip lithography at least does not disappear anytime soonDon't forget Applied Material (AMAT), they are behind all relevant manufacturing technology
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 500 | - | - | ||
| 48 | - | - | ||
| 5 000 | - | - | ||
| 188 | - | - | ||
| 1 822 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt